CareRx（CRRX）株式概要
ケアレックス・コーポレーションは、その子会社とともに、カナダの高齢者施設やその他の集合介護施設に薬局サービスを提供している。 詳細
CRRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CareRx Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | CA$3.38 |
| 52週高値 | CA$4.00 |
| 52週安値 | CA$2.70 |
| ベータ | 0.60 |
| 1ヶ月の変化 | 1.20% |
| 3ヶ月変化 | -9.87% |
| 1年変化 | 15.75% |
| 3年間の変化 | 53.64% |
| 5年間の変化 | -45.92% |
| IPOからの変化 | 9.03% |
最新ニュース
ナラティブ更新 • Jun 16
CRRX: Slightly Lower Growth Assumptions Will Still Support Long Term Upside
Analysts have adjusted their CareRx price target from CA$4.50 to CA$4.25, citing updated assumptions related to slightly lower revenue growth, a modestly adjusted discount rate, a marginally different profit margin outlook, and a small change in the expected future P/E. What's in the News No recent CareRx news items or key developments were provided in the available sources.
ナラティブ更新 • Jun 01
CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential
Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.Recent updates
ナラティブ更新 • Jun 16
CRRX: Slightly Lower Growth Assumptions Will Still Support Long Term Upside
Analysts have adjusted their CareRx price target from CA$4.50 to CA$4.25, citing updated assumptions related to slightly lower revenue growth, a modestly adjusted discount rate, a marginally different profit margin outlook, and a small change in the expected future P/E. What's in the News No recent CareRx news items or key developments were provided in the available sources.ナラティブ更新 • Jun 01
CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential
Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.ナラティブ更新 • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).ナラティブ更新 • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.ナラティブ更新 • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).ナラティブ更新 • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).ナラティブ更新 • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.ナラティブ更新 • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.ナラティブ更新 • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.ナラティブ更新 • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.ナラティブ更新 • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).ナラティブ更新 • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.ナラティブ更新 • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.ナラティブ更新 • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.分析記事 • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
新しいナラティブ • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.分析記事 • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...分析記事 • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...分析記事 • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...分析記事 • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...分析記事 • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...株主還元
| CRRX | CA Consumer Retailing | CA 市場 | |
|---|---|---|---|
| 7D | 0% | -1.5% | 0.6% |
| 1Y | 15.8% | 12.6% | 28.2% |
業界別リターン: CRRX過去 1 年間で12.6 % の収益を上げたCanadian Consumer Retailing業界を上回りました。
リターン対市場: CRRXは、過去 1 年間で28.2 % のリターンを上げたCanadian市場を下回りました。
価格変動
| CRRX volatility | |
|---|---|
| CRRX Average Weekly Movement | 3.5% |
| Consumer Retailing Industry Average Movement | 4.0% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in CA Market | 16.5% |
| 10% least volatile stocks in CA Market | 3.7% |
安定した株価: CRRX 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CRRXの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2001 | 1,483 | Puneet Khanna | www.carerx.ca |
CareRx Corporationは、その子会社とともに、カナダの高齢者施設やその他の集会施設に薬局サービスを提供している。同社は投薬管理、テクノロジー、プログラムサービスを提供している。介護施設、老人ホーム、福祉施設、グループホームにサービスを提供している。旧社名はセントリック・ヘルス・コーポレーションで、2020年6月にケアレックス・コーポレーションに社名変更した。CareRx Corporationは2001年に法人化され、カナダのトロントに本社を置いている。
CareRx Corporation 基礎のまとめ
| CRRX 基礎統計学 | |
|---|---|
| 時価総額 | CA$214.45m |
| 収益（TTM） | CA$27.07m |
| 売上高(TTM) | CA$374.61m |
7.9x
PER（株価収益率0.6x
P/SレシオCRRX は割高か？
公正価値と評価分析を参照収益と収入
| CRRX 損益計算書（TTM） | |
|---|---|
| 収益 | CA$374.61m |
| 売上原価 | CA$261.88m |
| 売上総利益 | CA$112.74m |
| その他の費用 | CA$85.67m |
| 収益 | CA$27.07m |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 29, 2026
| 一株当たり利益（EPS） | 0.43 |
| グロス・マージン | 30.09% |
| 純利益率 | 7.23% |
| 有利子負債／自己資本比率 | 36.1% |
CRRX の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
2.4%
現在の配当利回り14%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/26 04:07 |
| 終値 | 2026/07/24 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
CareRx Corporation 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |